Acrivon Therapeutics (ACRV) Operating Expenses (2021 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Acrivon Therapeutics was $78.37 million, down 17.0% year-over-year; for FY2025, it came in at $84.11 million, down 5.7% from FY2024.

• Annual Operating Expenses shows a four-year compound annual growth rate of 51.0% (FY2021 to FY2025).
• In prior years, Acrivon Therapeutics' Operating Expenses was $89.2 million in FY2024 (+32.9%), $67.1 million in FY2023 (+105.5%), $32.66 million in FY2022 (+101.8%) and $16.18 million in FY2021.
• The Q2 2026 figure stands as the lowest quarterly Operating Expenses since Q1 2024.
• On a year-over-year basis, Operating Expenses has declined in each of the last four quarters, with growth averaging 4.5% over the last eight quarters.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q3 2022, with growth of 258.5%; the weakest was Q3 2025, with a decline of 21.7%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $19.9 million (Q1 2026), $20.12 million (Q4 2025) and $19.69 million (Q3 2025).